Application of fidaxomicin in the preparation of medicines for treating related diseases and/or symptoms caused by dengue virus infection

A technology of dengue virus and fidaxomycin, applied in the field of medicine, can solve problems such as lack of effective drugs, and achieve the effects of high safety, strong binding ability, and high inhibition of dengue virus activity

Active Publication Date: 2020-05-26
SUN YAT SEN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is a lack of clinically approved effective drugs against dengue virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fidaxomicin in the preparation of medicines for treating related diseases and/or symptoms caused by dengue virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Inhibition of dengue virus (DENV) activity by fidaxomicin at the cellular level

[0020] Virus strain: Dengue virus DENV2 (NGC), cell line: A549

[0021] Detection method:

[0022] Fidaxomycin antiviral half effective dose (50% Effective Concentration, EC 50 ): DMSO, 6, 9, 12, 18, 24 μM Fidaxomycin saturated cells 1 hour in advance, 2 hours after virus infection, changed to virus-free medium containing corresponding concentration of drugs for 48 hours; collected cell supernatant, detected by plaque assay Plaque formation inhibition rate of different doses of fidaxomicin group relative to solvent group (DMSO) after virus infection.

[0023] Inhibition rate (%) = (1-the number of virus plaques in the administration group / the number of plaques in the solvent control group) 100%, calculated using the Forcast formula of EXCEL2013, when the inhibition rate is equal to 50%, the corresponding fidaxomicin Concentration, as EC 50 . The average value was obtained f...

Embodiment 2

[0027] Example 2 The inhibitory activity of Fidaxomycin to DENV2-prM protein in A549 cell line

[0028] Virus strain: Dengue virus DENV2 (NGC)

[0029] Cell line: A549

[0030] Detection method:

[0031] DMSO, 10, 50, 100 μM Fidaxomycin saturated the cells 1 hour in advance, and 2 hours after the virus infection, the virus-free medium containing the corresponding concentration of drugs was maintained for 48 hours; the cell pellet was collected, and Western blot electrophoresis was used to detect DENV2 in the cells under different treatments The relative expression of (NGC)-prM protein, GAPDH was used as internal reference protein. Such as figure 1 As shown, Fidaxomycin can effectively inhibit the membrane protein of DENV--DENV2-prM protein at a concentration of 10-50 μM. inhibition.

Embodiment 3

[0032] Example 3 Surface Plasmon Resonance Detection of Fidaxomycin and DENV2-NS5 Protein Affinity

[0033] This method adopts GE's Biacore T100 instrument and CM5 chip for experiments. First, the purified DENV2 (NGC)-NS5 protein is amino-coupled to the CM5 chip, and then flows through different concentrations of fidaxomicin. The instrument detects the adsorption on The mass change of the substance on the surface of the chip is calculated to calculate the affinity rate of the compound (K a ) vs. dissociation rate (K d ). Affinity = dissociation equilibrium constant (K D ), this value describes the binding strength between a small molecule and a protein molecule. The biological meaning is that when a small molecule binds to a protein 1:1, let 50% of the small molecule saturate the concentration of the protein molecule. The smaller the value, the stronger the binding. Usually, the affinity between small molecules and proteins calculated by this method is between 1 and 1000 μM...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of fidaxomicin in preparing medicines for treating related diseases and / or symptoms caused by dengue virus infection. The fidaxomicin, as a clinically approved drug for resisting clostridium difficile infection, is high in safety; and in addition, the fidaxomicin, which is high in activity of inhibiting the dengue virus infection and relatively strong in binding capacity with dengue virus non-structural protein NS5, is expected to function as a novel drug for resisting the dengue virus infection.

Description

technical field [0001] The invention belongs to the field of medicine, and more specifically relates to the application of fidaxomicin in the preparation of medicines for treating related diseases and / or symptoms caused by dengue virus infection. Background technique [0002] Fidaxomicin (trade name Dificid, also known as difimicin, lipiarmycin, tiacumicin B, formerly used names: PAR-101, OPT-80) is a bacterial DNA-dependent RNase inhibitor. Developed by Optimer for the initial treatment of Clostridium difficile infection (CDI) and the prevention of CDI recurrence, in January 2011, the US Food and Drug Administration (FDA) passed the approval of Fidaxomicin for the treatment of pediatric CDI Eligibility Application, In May 2011, the FDA approved fidaxomicin for the treatment of CDI in adults. [0003] The structure of Fidaxomycin is as follows: . [0004] Dengue virus belongs to the Flaviviridae family and is an RNA positive-strand virus. It is transmitted by mosquitoes ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P31/14
CPCA61K31/7048Y02A50/30
Inventor 黎孟枫袁洁朱勋于暕辰
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap